Primary Dural Diffuse Large B-cell Lymphoma: A Comprehensive Review of Survival and Treatment Outcomes
Publication date: Available online 28 September 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Zachary L. Quinn, Karam Zakharia, Janet L. Schmid, John J. Schmieg, Hana Safah, Nakhle S. SabaAbstractPrimary dural diffuse large B-cell lymphoma (PD-DLBCL) is a rare and aggressive B-cell non-Hodgkin lymphoma (NHL) that can present in intracranial or intraspinal locations. While the optimal management is unknown, PD-DLBCL therapy is often mirrored after primary central nervous system lymphoma (PCNSL) therapy and aggressive treatment with a high dose Methotrexate (MTX)-based regimen is frequently used. Our comprehensive, retrospective study of 24 reported cases of PD-DLBCL provide the most complete analysis of this rare disease including data on biology, treatment outcomes and survival. Our findings demonstrate good outcomes following induction treatment with R-CHOP, suggesting that these cases can be treated as DLBCL rather than PCNSL, obviating the need for more aggressive and toxic approaches. The durable responses following R-CHOP also confirm that PD-DLBCL is not protected by the blood brain barrier. Data in this paper were presented in part at the 2017 American Society of Hematology Annual Meeting, abstract # 4166.
Publication date: Available online 15 December 2019Source: Best Practice &Research Clinical HaematologyAuthor(s): Peter ValentAbstractChronic myelomonocytic leukemia (CMML) is defined by myelodysplasia, pathologic accumulation of monocytes and a substantial risk to transform to secondary acute myeloid leukemia (sAML). In recent years, minimal diagnostic criteria for classical CMML and CMML-variants were proposed. Moreover, potential pre-stages of CMML and interface conditions have been postulated. Oligomonocytic CMML is a condition where the absolute peripheral blood monocyte count does not reach a diagnostic level but...
ConclusionsOral complications in HSCT survivors are common and may include GVHD, dry mouth, and taste changes. All patients must be screened prior to HSCT and followed up by a dentist periodically to assess the oral health status and modify treatment, if needed.
ConclusionsHere, we reported a series of 29 cases of MRONJ with related mandibular or palatal tori among 391 consecutive patients in the Copenhagen ONJ Cohort . We documented that 59% of these cases were associated with trauma, and that in some cases, trauma was preventable (e.g., trauma from impression taking and intubation). Dentists as well as anesthesiologists should be aware of the presence of tori in patients on antiresorptive therapy. Surgical treatment was more successful (100%) compared with nonsurgical treatment (40%).
ConclusionsAnalysis of Penn OM clinical practices emphasized the breadth and multidisciplinary nature of OM services, as well as the importance of comprehensive postdoctoral training in all domains of OM for future OM specialists.
ConclusionsMaxillofacial manifestation of bone metastasis is common but is often overlooked. Therefore, it should be considered in the differential diagnosis when a patient with a history of antiresorptive medications presents with a gingival mass and/or exophytic bone. Good clinical judgment and well-timed bone biopsy and diagnostic imaging can lead to the correct diagnosis and optimal treatment.
ConclusionsOral mucosal manifestation of NHL is rare and, in most cases, the first sign of relapse. Many NHLs can present in oral soft tissues, and most are fatal, so clinicians should take NHL into consideration when making their differential diagnosis. NHL lesions can mimic periodontal disease, acute abscess, or even other malignancies.
ConclusionsDental providers should consider malignancy, including lymphoma, although uncommon, in the differential diagnosis of jaw pain, particularly when thorough evaluation fails to disclose a dental etiology, routine dental interventions fail to control symptoms, or there are atypical clinical or radiographic findings.
ConclusionsThe application of this panel of markers can help the diagnosis of oral MLs, in particular the distinction between fibroblastic, myofibroblastic, and muscle cells proliferation.
ConclusionsSerum metabolite concentration of MTX and BB should be monitored as relative predictors of higher OM risk.
We report a series of 12 cases of oral aspergillosis with an age range from 21 to 63 years (mean, 42 y), 7 women, 5 men, whose underlying diseases were acute myeloid leukemia (n = 9) and chronic myeloid leukemia in blastic crisis (n = 3). Primary sites and symptoms were: 2 cases in the nasal cavity presenting as rhinorrhea and fever, 5 cases in the paranasal sinus (2 with pain, 1 with fever and 2 with pain and fever), and 5 cases in the oral mucosa who presented on ly with pain. All cases localized in paranasal sinuses were detected by computed tomography while in the nasal cavity; however, none were detected by i...